Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJ3I1Q)

Drug Name
Niflumic Acid Drug Info
Synonyms
Actol; Donalgin; Flunir; Forenol; Landruma; NFL; Niflactol; Niflam; Niflugel; Niflumate; Nifluril; Acide niflumique; Acide niflumique [French]; Acido niflumico; Acido niflumico [Italian]; Acidum niflumicum; Nifluminic acid; UPSA Conseil Brand of Niflumic Acid; Upsamedica Brand of Niflumic Acid; N 0630; SC 1332; UP 83; UPSA Brand 1 of Niflumic Acid; UPSA Brand 2 of Niflumic Acid; Acid, Niflumic; Acide niflumique [INN-French]; Acido niflumico [INN-Spanish]; Acidum niflumicum [INN-Latin]; Niflugel (TN); Niflumic acid (INN); Niflumic acid [INN:DCF]; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino; Aza-2 dimethyl-2',3' (tetrazolyl-5)-6 diphenylamino [French]; 2-(3-(Trifluoromethyl)-phenyl)aminonicotinic acid; 2-(3-(Trifluoromethyl)anilino)nicotinic acid; 2-(3-Trifluoromethyl-phenylamino)-nicotinic acid; 2-(3-Trifluoromethylanilino)nicotinic Acid; 2-(3-[Trifluoromethyl]anilino)nicotinic acid; 2-(A,A,A-Trifluoro-m-toluidino)nicotinic acid; 2-(alpha,alpha,alpha-Trifluoro-m-toluidino)nicotinic acid; 2-[(3-TRIFLUOROMETHYL)PHENYL]AMINO-3-PYRIDINE-CARBOXYLIC ACID; 2-[(3-Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid; 2-[(3-Trifluoromethylphenyl)amino]nicotinic Acid; 2-[3-(Trifluoromethyl)anilino]nicotinic acid; 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid; 2-[alpha,alpha,alpha-trifluoro-m-toluidino]-nicotinic acid; 2-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}NICOTINIC ACID; 2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid; 39690A
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
4488
ChEBI ID
CHEMBL63323
CAS Number
CAS 4394-00-7
TTD Drug ID
D00HGB
VARIDT Drug ID
DR01158
INTEDE Drug ID
DR1153

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Graft-versus-host disease 2.11 0.00e+0 32/42 (76.19%) HLA-DRA;HLA-DPA1;IL1B;...
Type I diabetes mellitus 2.03 0.00e+0 38/43 (88.37%) HLA-DRA;HLA-DPA1;GAD1;...
Cytosolic DNA-sensing pathway 1.96 3.48e-3 52/63 (82.54%) IKBKE;CCL5;CCL4;...
Systemic lupus erythematosus 1.94 2.61e-3 45/135 (33.33%) HLA-DRA;CTSG;HLA-DPA1;...
Allograft rejection 1.93 2.09e-3 32/38 (84.21%) HLA-DRA;HLA-DPA1;HLA-DRB1;...
RIG-I-like receptor signaling pathway 1.90 1.74e-3 64/70 (91.43%) IKBKE;ISG15;DDX58;...
Fc gamma R-mediated phagocytosis 1.85 5.96e-3 79/97 (81.44%) MARCKS;PIP5K1B;PIP5K1A;...
Autoimmune thyroid disease 1.84 6.52e-3 46/53 (86.79%) HLA-DRA;HLA-DPA1;CGA;...
Epstein-Barr virus infection 1.83 6.96e-3 189/202 (93.56%) IKBKE;PSMD4;ISG15;...
DNA replication 1.82 1.15e-2 34/36 (94.44%) PCNA;RFC2;SSBP1;...
Influenza A 1.74 2.75e-2 156/172 (90.7%) IKBKE;TNFSF10;CCL5;...
Antigen processing and presentation 1.73 3.30e-2 60/78 (76.92%) HLA-DRA;CD74;HLA-DPA1;...
Toll-like receptor signaling pathway 1.72 3.13e-2 94/104 (90.38%) IKBKE;CCL5;CCL4;...
Yersinia infection 1.66 4.77e-2 120/137 (87.59%) LCP2;GNAQ;PIP5K1B;...
Dilated cardiomyopathy -1.68 4.89e-2 86/96 (89.58%) LAMA2;ITGA3;SGCB;...
Hypertrophic cardiomyopathy -1.72 4.27e-2 81/90 (90%) LAMA2;ITGA3;SGCB;...
Retinol metabolism -1.77 2.88e-2 41/68 (60.29%) UGT2B15;UGT2B28;ALDH1A3;...
Collecting duct acid secretion -1.77 3.02e-2 22/27 (81.48%) ATP6V0A2;ATP6V1C1;ATP6V1A;...
Metabolism of xenobiotics by cytochrome P450 -1.80 1.92e-2 49/77 (63.64%) CYP1B1;ALDH3B1;GSTA4;...
Arginine and proline metabolism -1.83 2.11e-2 39/50 (78%) MAOB;AMD1;ALDH4A1;...
Ascorbate and aldarate metabolism -1.85 2.40e-2 15/30 (50%) UGT2B15;UGT2B28;ALDH3A2;...
Arginine biosynthesis -1.86 2.88e-2 17/22 (77.27%) GLS;GLUL;GOT1;...
Nitrogen metabolism -1.90 2.40e-2 16/17 (94.12%) GLUL;CA3;CA2;...
Phenylalanine metabolism -1.91 3.84e-2 14/17 (82.35%) GLYAT;MAOB;ALDH3B1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H